What is the translation of " KONTROLIRANIM ISPITIVANJIMA " in English?

• controlled studies
• controlled trials

Examples of using Kontroliranim ispitivanjima in Croatian and their translations into English

Tablica 2 Nuspojave prijavljene u kontroliranim ispitivanjima faze 2 i faze 3.
Table 2 Adverse reactions reported in phase 2 and phase 3 controlled trials.

U kontroliranim ispitivanjima djelotvornost je dokazana u bolesnika liječenih do 29 tjedana.
Efficacy was demonstrated in controlled trials in patients treated for up to 29 weeks.

Tablica 1: Nuspojave opažene objedinjenim pivotalnim kontroliranim ispitivanjima faze 3.
Table 1: Adverse reactions observed in pooled pivotal phase 3 controlled clinical studies.

U kontroliranim ispitivanjima koja su mjerila postotak vremena provedenog u svakoj fazi sna pokazalo se da Sonata održava faze sna.
Sonata has been shown to preserve sleep stages in controlled studies that measured the percentage of sleep time spent in each sleep stage.

U tablici 2 navode se nuspojave prijavljene u dugotrajnim, kontroliranim ispitivanjima faze 2 i faze 3.
Table 2 lists adverse reactions reported in long term phase 2 and phase 3 controlled trials.

U aktivno kontroliranim ispitivanjima svi su bolesnici imali> 6 godina(raspon 6-66 godina) uz FEV1 na probiru između 24% i 76% od predviđene vrijednosti.
In the active controlled studies, all patients were aged> 6years old(range 6-66 years) with an FEV1% predicted at screening of between 24% and 76.

U bolesnika s nekompliciranom hipertenzijom liječenom Rasilamlom u kratkotrajnim kontroliranim ispitivanjima incidencija hipotenzije bila je niska 0, 2.
In patients with uncomplicated hypertension treated with Rasilamlo in short-term controlled trials, the incidence of hypotension was low 0.2.

U dugotrajnim(26 tjedana ili duže) kontroliranim ispitivanjima reakcije na mjestu injiciranja prijavljene su u otprilike 2% bolesnika koji su primali lijek Victoza.
Injection site reactions have been reported in approximately 2% of patients receiving Victoza in long term(26 weeks or longer) controlled trials.

Ukupna incidencija nuspojava prijavljenih uz telmisartan(41, 4%) obično je bila usporediva s placebom(43, 9%) u placebom kontroliranim ispitivanjima.
The overall incidence of adverse reactions reported with telmisartan(41.4%) was usually comparable to placebo(43.9%) in placebo controlled trials.

Sljedeća tablica prikazuje nuspojave prijavljene u placebom kontroliranim ispitivanjima, u kojima je 1965 hipertenzivnih bolesnika primalo irbesartan.
The following table presents the adverse medicinal product reactions that were reported in placebo- controlled trials in which 1,965 hypertensive patients received irbesartan.

Utjecaj CYP2C19 genotipa na kliničke ishode u bolesnika liječenih klopidogrelom nije procijenjen u prospektivnim, randomiziranim, kontroliranim ispitivanjima.
The influence of CYP2C19 genotype on clinical outcomes in patients treated with clopidogrel has not been evaluated in prospective, randomised, controlled trials.

U placebom kontroliranim ispitivanjima privremeni nedostatak željeza bio je izraženiji u bolesnika liječenih lijekom NeoRecormon nego u kontrolnim skupinama vidjeti dio 4.4.
In placebo controlled trials temporary iron deficiency was more pronounced in patients treated with NeoRecormon than in controls see section 4.4.

Klinička sigurnost lijeka OZURDEX u bolesnika s dijabetičkim makularnim edemom utvrđena je u dvama randomiziranima, dvostruko slijepima, placebom kontroliranim ispitivanjima faze 3.
The clinical safety of OZURDEX in patients with diabetic macular oedema was assessed in two phase 3 randomized, double-masked, sham-controlled studies.

U svim kontroliranim ispitivanjima, liječenje je zbog nuspojava prekinulo 2,0% bolesnika na kojima je primijenjen flaster Qutenza i 0,9% bolesnika koji su primali kontrolu.
In all controlled trials, the discontinuation rate due to adverse reactions was 2.0% for patients receiving Qutenza and 0.9% for patients receiving control..

Najčešća klinička toksičnost nevirapina je osip, a osip koji se pripisuje Viramuneu uz kombiniranu terapiju u kontroliranim ispitivanjima događa se kod bolesnika 12, 5.
The most common clinical toxicity of nevirapine is rash, with Viramune attributable rash occurring in 12.5% of patients in combination regimens in controlled studies.

U dvostruko slijepim placebo kontroliranim ispitivanjima 529 bolesnika bilo je liječeno razagilinom 1 mg/dan kroz 212 bolesničkih godina, a 539 bolesnika je primalo placebo kroz 213 bolesničkih godina.
In the double blind placebo controlled studies, 529 patients were treated with rasagiline 1 mg/day for 212 patient years and 539 patients received placebo for 213 patient years.

Podaci iz dugotrajnih nastavaka ispitivanja do 24 mjeseca pokazali su bubrežni sigurnosni profil dosljedan onom opaženom u placebom kontroliranim ispitivanjima.
Data from the long-term extension studies until 24 months revealed a renal safety profile consistent with that observed in the placebo- controlled studies.

U kontroliranim ispitivanjima s djelatnim usporednim lijekom stope su iznosile 24%(10,5% umjereno ili teško) za ulipristalacetat i 60,4%(39,6% umjereno ili teško) za bolesnike liječene leuprorelinom.
In the active comparator controlled study the rates were 24%(10.5% moderate or severe) for ulipristal acetate and 60.4%(39.6% moderate or severe) for leuprorelin-treated patients.

Reakcije na mjestu injekcije prijavljene su u približno 5,1% ispitanika koji su primali eksenatid s trenutnim oslobađanjem u dugoročnim(16 tjedana ili dulje) kontroliranim ispitivanjima.
Injection site reactions have been reported in approximately 5.1% of subjects receiving immediate-release exenatide in long-term(16 weeks or longer) controlled trials.

U kontroliranim ispitivanjima GEMINI I i GEMINI II, 5%(3 od 61) bolesnika koji su imali nuspojavu ocijenjenu od strane ispitivača kao RPI bili su trajno pozitivni na anti-vedolizumab protutijela.
In GEMINI I and II controlled studies, 5%(3 of 61) of the patients who had an adverse event assessed by the investigator as an IRR were persistently anti-vedolizumab antibody-positive.

Slične promjene opažene su u bolesnika liječenih metforminom(relativno smanjenje hemoglobina za 3-4% i hematokrita za 3, 6-4,1%) u usporednim kontroliranim ispitivanjima s pioglitazonom.
Similar changes were seen in metformin(haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) treated patients in comparative controlled trials with pioglitazone.

U kontroliranim ispitivanjima GEMINI I i II, stopa ozbiljnih infekcija iznosila je 0, 07 po bolesnik-godini u bolesnika liječenih vedolizumabom te 0, 06 po bolesnik-godini u bolesnika liječenih placebom.
In GEMINI I and II controlled studies, the rate of serious infections was 0.07 per patient year in vedolizumab-treated patients and 0.06 per patient year in placebo-treated patients.

Bolesnici liječeni eksenatidom s trenutnim oslobađanjem su u otvorenim produžecima ispitivanjima nakon 82 tjedna doživjeli slične vrste nuspojava kao i u kontroliranim ispitivanjima.
Immediate-release exenatide-treated patients in the open-label extension studies at 82 weeks experienced similar types of adverse events observed in the controlled trials.

Približno polovica od tih 6%(3% ukupnog broja bolesnika koji su primili eksenatid s trenutnim oslobađanjem u kontroliranim ispitivanjima) nije imala vidljiv glikemijski odgovor na trenutno oslobađajući eksenatid.
About half of this 6%(3% of the total patients given immediate-release exenatide in the controlled studies), had no apparent glycaemic response to immediate-release exenatide.

Tijekom liječenja Tecfiderom u placebom kontroliranim ispitivanjima MS-a, srednja vrijednost broja limfocita smanjila se za otprilike 30% od početne vrijednosti tijekom prve godine nakon čega je uslijedio plato vidjeti dio 4.8.
During treatment with Tecfidera in the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% from baseline at one year and then plateaued see section 4.8.

Dnevna smanjenja eritema tijekom prvog mjeseca primjene(mjereno CEA i PSA skalama) bila su slična onima opaženima u kontroliranim ispitivanjima, a ta su se smanjenja mogla postići do 12 mjeseci bez prividnog gubitka učinka tijekom vremena.
Daily reductions in erythema for the first month of use(as measured with the CEA and PSA scales) were similar to those observed in the controlled trials, and those reductions were achievable for up to 12 months with no apparent loss of effect over time.

U klinički kontroliranim ispitivanjima efavirenza simptomi živčanog sustava umjerenog do teškog intenziteta uočeni su u 19%(teški oblik 2%) pacijenata, a u 2% pacijenata terapija je zbog tih simptoma prekinuta.
In clinical controlled studies of efavirenz, nervous system symptoms of moderate to severe intensity were experienced by 19%(severe 2%) of patients, and 2% of patients discontinued therapy due to such symptoms.

Na temelju dostupnih podataka od bolesnika koji su primali sinakalcet u placebom kontroliranim ispitivanjima i ispitivanjima na jednoj skupini, najčešće zabilježene nuspojave bile su mučnina i povraćanje.
Based on available data from patients receiving cinacalcet in placebo controlled studies and single-arm studies the most commonly reported adverse reactions were nausea and vomiting.

U kontroliranim ispitivanjima GEMINI I i GEMINI II, 4% bolesnika liječenih vedolizumabom i 3% bolesnika liječenih placebom imali su nuspojave koje su ispitivači definirali kao reakciju povezanu s infuzijom(RPI) vidjeti dio 4.4.
In GEMINI I and II controlled studies, 4% of vedolizumab-treated patients and 3% of placebo-treated patients experienced an adverse event defined by the investigator as infusion-related reaction(IRR) see section 4.4.

Sljedeće nuspojave prijavljene su u placebom kontroliranim ispitivanjima u kojima su ispitanici primali anesteziju i/ili neuromuskularne blokatore 1078 ispitanika primilo je sugamadeks naspram 544 koji su primili placebo.
The following adverse reactions were reported in placebo controlled trials where subjects received anaesthesia and/or neuromuscular blocking agents 1,078 subject exposures to sugammadex versus 544 to placebo.